Brainstorm Cell Therapeutics, Inc. (OTC BB: BCLI), a leading developer of stem cell technologies, is committed to providing treatments for neurodegenerative diseases that are currently incurable. The company’s focus is on developing NTF cells from the patient’s own bone marrow to treat, Parkinson, ALS, and Spinal Cord Injury. The Brainstorm management and scientific teams are devoted to the company’s mission to regenerate the mind in their lifetime. For further information, visit the Company’s web site at www.brainstorm-cell.com.
- 17 years ago
QualityStocks
Brainstorm Cell Therapeutics, Inc. (OTC BB: BCLI)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – NextPlat Corp (NASDAQ: NXPL) Narrows Q2 Loss 66% as E-Commerce Growth Offsets Healthcare Headwinds
NextPlat (NASDAQ: NXPL, NXPLW), a global consumer products and services company in healthcare and technology,…
-
QualityStocksNewsBreaks – Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) Stands Distinct Against Walker Lane Backdrop
Lahontan Gold (TSX.V: LG) (OTCQB: LGCXF) is positioned as investors view the Walker Lane corridor in…
-
QualityStocksNewsBreaks – Solowin Holdings (NASDAQ: SWIN) Targets $1 Billion AUM for Tokenized USD Money Market Product by Year-End 2025
Solowin (NASDAQ: SWIN), a financial services firm bridging traditional and digital assets, announced an initiative…